Last reviewed · How we verify
NCT05824702
A Social Network Approach for Improving Medication Assisted Treatment and HIV Prevention and Medical Care Among People Who Inject Drugs in Ukraine
NA trial testing Peer education & communications in HIV in 241 participants. Completed in 1 September 2025.
1 September 2025
Quick facts
| Lead sponsor | Johns Hopkins Bloomberg School of Public Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 241 |
| Start date | 20 September 2023 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across Ukraine |
Drugs / interventions tested
- Peer education & communications
- Standard of care educational
Conditions studied
- HIV — all drugs for HIV →
Sponsor
Johns Hopkins Bloomberg School of Public Health
Who can join
18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to pilot a peer education for people on medication assisted treatment (MAT). People on MAT will be trained to be peer educators and provide outreach to the educators social network members who inject drugs, some of whom will be HIV positive.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05824702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other Johns Hopkins Bloomberg School of Public Health trials
Trials by the same sponsor.
- NCT07458230 — Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation: · Phase 3 · not yet recruiting
- NCT07227558 — Improving Information Sharing Between Family Caregivers and Home Care Aides · NA · recruiting
- NCT07536126 — Testing Non-Nutrition Menu Labels on Food Selections · NA · not yet recruiting
- NCT06426004 — Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland · NA · not yet recruiting
- NCT07344142 — Improving Digital Wellbeing in Saudi Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05824702 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins Bloomberg School of Public Health
- Last refreshed: 6 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05824702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing